Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2015

Publisher Name :
Date: 31-Mar-2015
No. of pages: 67
Inquire Before Buying

Global Markets Direct’s, ‘Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2015’, provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • The report provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome)

  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in the therapeutics development for Interstitial Cystitis (Painful Bladder Syndrome) and enlists all their major and minor projects

  • The report summarizes all the dormant and discontinued pipeline projects

  • A review of the Interstitial Cystitis (Painful Bladder Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • A detailed assessment of monotherapy and combination therapy pipeline projects

  • Coverage of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type

  • Latest news and deals relating related to pipeline products


Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome)

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2015

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Interstitial Cystitis (Painful Bladder Syndrome) Overview 7
Therapeutics Development 8
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Overview 8
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis 9
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Development by Companies 10
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Investigation by Universities/Institutes 11
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Development by Companies 14
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Investigation by Universities/Institutes 15
Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development 16
Afferent Pharmaceuticals, Inc. 16
Allergan, Inc. 17
Aquinox Pharmaceuticals Inc. 18
Kytogenics Pharmaceuticals, Inc. 19
Lipella Pharmaceuticals, Inc. 20
Qu Biologics Inc. 21
Urigen Pharmaceuticals, Inc. 22
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
(lidocaine + heparin) - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AF-219 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AQX-1125 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
GM-0111 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
GM-1111 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
lidocaine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
LP-08 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
mesalamine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
NEO-5024 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
NEO-5937 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
onabotulinumtoxin A liposomal - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
QBECP-SSI - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Interstitial Cystitis (Painful Bladder Syndrome) - Recent Pipeline Updates 53
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects 58
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products 59
Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones 60
Featured News & Press Releases 60
Mar 02, 2015: Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis 60
Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome 60
Jun 02, 2014: Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase 2 Trials of AQX-1125, Including Acceptance of U.S. IND 61
Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219 62
Jul 23, 2013: Aquinox Pharmaceuticals commences Phase II clinical trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis 63
Apr 02, 2013: Taris Doses First Patient In Second Phase II Clinical Study Of LiRIS For Treatment Of Interstitial Cystitis 63
Nov 30, 2011: TARIS Initiates Phase II Clinical Study With LiRIS In Interstitial Cystitis Patients 64
Jun 30, 2011: Urigen Provides Development Update For URG101 64
Mar 09, 2011: TARIS Initiates Clinical Study In Interstitial Cystitis Patients 64
Aug 18, 2010: Urigen Reports Type C Meeting With FDA For URG101 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2015 8
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Afferent Pharmaceuticals, Inc., H1 2015 16
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Allergan, Inc., H1 2015 17
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Aquinox Pharmaceuticals Inc., H1 2015 18
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kytogenics Pharmaceuticals, Inc., H1 2015 19
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Lipella Pharmaceuticals, Inc., H1 2015 20
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Qu Biologics Inc., H1 2015 21
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Urigen Pharmaceuticals, Inc., H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Assessment by Combination Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 32
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics - Recent Pipeline Updates, H1 2015 53
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects, H1 2015 58
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products, H1 2015 59

List of Figures

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2015 8
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Top 10 Targets, H1 2015 25
Number of Products by Stage and Top 10 Targets, H1 2015 26
Number of Products by Top 10 Mechanism of Actions, H1 2015 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Top 10 Routes of Administration, H1 2015 29
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30
Number of Products by Top 10 Molecule Types, H1 2015 31
Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

  • Nocturia - Pipeline Review, H1 2017
    Published: 28-Feb-2017        Price: US 2000 Onwards        Pages: 33
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nocturia - Pipeline Review, H1 2017, provides an overview of the Nocturia (Genito Urinary System And Sex Hormones) pipeline landscape.Nocturia is defined as need to urinate at least twice during the night. This condition becomes more common as people age and occurs in both men and women, sometimes for different reasons. Causes of nocturia include congestive heart failure, edema of lower extremities, sleeping d......
  • Urinary Incontinence - Pipeline Review, H1 2017
    Published: 28-Feb-2017        Price: US 2000 Onwards        Pages: 66
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Pipeline Review, H1 2017, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape.Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder's contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors includ......
  • Interstitial Cystitis (Painful Bladder Syndrome)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Interstitial Cystitis (Painful Bladder Syndrome)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Interstitial Cystitis (Painful Bladder Syndrome) Report is to understand the market and pipeline status of the drugs around the Interstitial Cystitis (Painful Bladder Syndrome) to explore th......
  • Interstitial Cystitis  - Epidemiology Forecast To 2023
    Published: 01-Jan-2017        Price: US 2750 Onwards        Pages: 60
    DelveInsight "Interstitial Cystitis - Epidemiology Forecast To 2023" provides an overview of the epidemiology trends of Interstitial Cystitis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Interstitial Cystitis prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need ass......
  • Bladder Pain-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Bladder Pain-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Bladder Pain. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fun......
  • Interstitial Cystitis-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Interstitial Cystitis-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Interstitial Cystitis. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations,......
  • Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Interstitial Cystitis (Painful Bladder Syndrome). The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activ......
  • Urethritis-API Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have......
  • Urinary Incontinence-API Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs